Fig. 5.

Utility of SACC-PHHs for antiviral drug testing. a Schematic of HBV life cycle indicating the presumed mechanism of action of myr-PreS1 entry inhibitor, TDP2 inhibitors and ETV. b Prophylactic treatment with myr-preS1-derived peptides in SACC-PHH 96-well format (HU1007 mixed donor). Prophylactic c and therapeutic d drug dosing of SACC-PHHs (mixed donor HU1008) in 96-well format for nucleotide analog ETV and TDP2 inhibitors (JK-3-121, SV-F-153), x-axis: concentration of different drugs. y-axis: amount of HBsAg secretion normalized to that secreted by HBVcc infected untreated control cells. For HBVcc infections and drug treatments, six biological replicates were performed. All data are presented as means ± s.d